Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.52 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL10840728 | 0.84 | SLC22A1 (0.55) | SLC22A1SLC22A2RECQLTSHRGLA | |
| Tetrabuthylammonium SCHEMBL1259012 | 0.84 | SLC22A1 (0.55) | SLC22A1SLC22A2RECQLTSHRGLA | |
| Tetrabuthylammonium SCHEMBL991019 | 0.84 | SLC22A1 (0.55) | SLC22A1SLC22A2RECQLTSHRGLA | |
| Tetrabuthylammonium SCHEMBL5574939 | 0.84 | SLC22A1 (0.55) | SLC22A1SLC22A2RECQLTSHRGLA | |
| Tetrabuthylammonium SCHEMBL158552 | 0.84 | SLC22A1 (0.60) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL27522614 | 0.84 | SLC22A1 (0.60) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL243898 | 0.84 | SLC22A1 (0.67) | SLC22A1SLC22A2RECQLTSHRGLA | |
| Tetrabuthylammonium SCHEMBL7757825 | 0.83 | SLC22A1 (0.52) | SLC22A1SLC22A2RECQLTSHRGLA | |
| Tetrabuthylammonium SCHEMBL28818846 | 0.83 | SLC22A1 (0.52) | SLC22A1SLC22A2RECQLTSHRGLA | |
| Tetrabuthylammonium SCHEMBL9795123 | 0.81 | SLC22A1 (0.63) | SLC22A1SLC22A2RECQLTSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228564-A1 | PROCESSES OF ENANTIOSELECTIVELY FORMING AN AMINOXY COMPOUND AND AN 1,2-OXAZINE COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-08-14 | — | — | US | disclosed |
| US-20130341573-A1 | PHOTOREFRACTIVE COMPOSITION COMPRISING ELECTROLYTES IN A PHOTOREFRACTIVE LAYER AND METHOD OF MAKING THEREOF | NITTO DENKO CORPORATION (JP) | 2013-12-26 | — | — | US | disclosed |
| EP-2612198-A1 | SYSTEMS AND METHODS FOR IMPROVING THE PERFORMANCE OF A PHOTOREFRACTIVE DEVICE BY UTILIZING ELECTROLYTES | Nitto Denko Corporation (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-20130163086-A1 | SYSTEMS AND METHODS FOR IMPROVING THE PERFORMANCE OF A PHOTOREFRACTIVE DEVICE BY UTILIZING ELECTROLYTES | NITTO DENKO CORPORATION (JP) | 2013-06-27 | — | — | US | disclosed |
| WO-2012116071-A1 | PHOTOREFRACTIVE COMPOSITION COMPRISING ELECTROLYTES IN A PHOTOREFRACTIVE LAYER AND METHOD OF MAKING THEREOF | NITTO DENKO CORPORATION (JP) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012031025-A1 | SYSTEMS AND METHODS FOR IMPROVING THE PERFORMANCE OF A PHOTOREFRACTIVE DEVICE BY UTILIZING ELECTROLYTES | NITTO DENKO CORPORATION (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228564-A1 | PROCESSES OF ENANTIOSELECTIVELY FORMING AN AMINOXY COMPOUND AND AN 1,2-OXAZINE COMPOUND | AHR, CYP2S1, CYP1A1 | SLC22A1 3282/4885SLC22A2 3095/4885RECQL 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.